Bronstein, Gewirtz & Grossman, LLC Class Action MU, GSM & TYME

NEW YORK, NY / ACCESSWIRE / February 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Micron Technology, Inc. (MU)

Class Period: September 26, 2017- November 19, 2018

Lead Plaintiff Deadline: March 25, 2019
For more info: www.bgandg.com/mu

The Complaint alleges that throughout the Class Period Defendants made materially false and misleading statements and/or failed to disclose that Micron was engaged in a price-fixing conspiracy with Samsung Electronics and SK Hynix, and that such unlawful behavior could lead to severe sanctions against the Company.

Ferroglobe PLC (GSM)

Class Period: August 21, 2018 - November 26, 2018
Lead Plaintiff Deadline: March 25, 2019
For more info: www.bgandg.com/gsm

The Complaint alleges that throughout the Class Period Defendants made materially false and misleading statements and/or failed to disclose that: (1) that there was excess supply of the Company's products; (2) that demand for the Company's products was declining; (3) that, as a result, the pricing of the Company's products would be materially impacted; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Tyme Technologies, Inc. (TYME)
Class Period: March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
For more info: www.bgandg.com/tyme

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (2) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (3) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (4) as a result, Tyme's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on accesswire.com:
https://www.accesswire.com/536560/Bronstein-Gewirtz-Grossman-LLC-Class-Action-MU-GSM-TYME